Mind Medicine (MindMed) Inc.

$20.69 USD

$0.09 (0.44%)

Volume: 298.41K
Average Volume: 2.53M
Market Capitalization: $1.56B
P/E Ratio: -8.28
Dividend Yield: 0.00%
Price Target: $20.00

Year High: $21.08
Year Low: $4.70
Day High: —
Day Low: —
Payout Ratio: $0.00
Current Ratio: $4.69

Industry, Sector & symbol

Stock Exchange	NASDAQ
CEO	Robert Barrow
Industry	Biotechnology
Sector	Healthcare
Current Symbol	MNMD
CUSIP	60255C109
CIK	0001813814
Web	https://www.mindmed.co
Phone	650 208 2454
Currency	USD
Employees	74
Country	CA

Liquidity

Debt-to-Equity Ratio	0.15
Payout Ratio	0.00
Current Ratio	4.69
Quick Ratio	4.69
Cash Ratio	3.24

Sales & Book Value

Annual Sales	-$
Price / Sales	0.00
Cash Flow	-1.60
Price / Cash Flow	-8.97
Price / Book	8.07

Price Target and Rating

Average Stock Price Forecast	$20.00
High Stock Price Forecast	$28.00
Low Stock Price Forecast	$14.00
Forecast Upside/Downside	3.45%
Consensus Rating	N/A
Rating Score(0-5)	0
Research Coverage	1 Analysts

Profitability

EPS (Most Recent Fiscal Year)	-$2.06
Trailing P/E Ratio	-8.28
PEG Ratio	0.11
P/E Growth	0.11
Net Income	-$183.79M
Net Margin	0.00%
Pretax Margin	0.00%
Return on Equity	-102.48%
Return on Assets	-59.19%

Financials Score

AltmanZ Score	4.51
Piotroski Score	1.00
Working Capital	299.45M
Total Assets	401.29M
Ebit	-211.45M
Market Cap	1.56B
Total Liabilities	122.44M

Poll Results

About Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Stock

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering new treatments for various brain health conditions, encompassing psychiatric disorders, addiction, pain, and neurological ailments. Among its key pipeline assets is MM-120, currently undergoing Phase 2 clinical trials. This candidate is being investigated for its potential in addressing generalized anxiety disorder, attention deficit hyperactivity disorder (ADHD), and chronic pain. Furthermore, MM-110, an a3ß4 nicotinic cholinergic receptor antagonist, has successfully completed Phase 1 studies for managing opioid withdrawal. The company's portfolio also includes MM-402, an R-enantiomer of 3,4-methylenedioxymethamphetamine, aimed at treating the core symptoms associated with autism spectrum diso ... rder. Its corporate headquarters are situated in Vancouver, Canada.

Frequently Asked Questions

What is the current Mind Medicine (MindMed) Inc. (MNMD) stock price?: Mind Medicine (MindMed) Inc.(NASDAQ:MNMD) stock price is $20.69 in the last trading session. During the trading session, MNMD stock reached the peak price of $21.08 while $4.7 was the lowest point it dropped to. The percentage change in MNMD stock occurred in the recent session was 0.44% while the dollar amount for the price change in MNMD stock was $0.09.
MNMD's industry and sector of operation?: The NASDAQ listed MNMD is part of Biotechnology industry that operates in the broader Healthcare sector.
Who are the executives of MNMD?: Robert Barrow | Chief Executive Officer & Director
Brandi L. Roberts | Chief Financial Officer
Scott Freeman | Co-Founder & Clinical Advisor
Leonard Latchman | Co-founder
Mark R. Sullivan | Chief Legal Officer & Corporate Secretary
How many employees does MNMD have?: Number of MNMD employees currently stands at 74. MNMD operates from 1055 West Hastings Street, Vancouver, BC V6E 2E9, CA.

Link for MNMD official website?: Official Website of MNMD is: https://www.mindmed.co
How do I contact MNMD?: MNMD could be contacted at phone #650 208 2454 and can also be accessed through its website. MNMD operates from 1055 West Hastings Street, Vancouver, BC V6E 2E9, CA.
How many shares of MNMD are traded daily?: The average number of MNMD shares traded daily for last 3 months was 2.53M.
What is the market cap of MNMD currently?: The market value of MNMD currently stands at $1.56B with its latest stock price at $20.69